|33.64||+1.04||+3.19%||Vol 300.63K||1Y Perf 568.40%|
|Apr 16th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||-||Analyst Rating||— — 0.00|
|Potential %||-||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Market Cap||-||Earnings Rating||—|
|Price Range Ratio 52W %||19.62||Earnings Date||-|
Today's Price Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||791.11K|
|Avg. Monthly Volume||1.08M|
|Avg. Quarterly Volume||680.66K|
Greenwich LifeSciences Inc. (NYSE: GLSI) stock closed at 33.64 per share at the end of the most recent trading day (a 3.19% change compared to the prior day closing price) with a volume of 301.15K shares and market capitalization of 0.0000. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 3 people. Greenwich LifeSciences Inc. CEO is Snehal Patel.
The one-year performance of Greenwich LifeSciences Inc. stock is 568.4%, while year-to-date (YTD) performance is -7.76%. GLSI stock has a five-year performance of %. Its 52-week range is between 3.26 and 158.07, which gives GLSI stock a 52-week price range ratio of 19.62%
Greenwich LifeSciences Inc. currently has a PE ratio of -252.50, a price-to-book (PB) ratio of 23.48, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -12.98%, a ROC of -22.51% and a ROE of -14.18%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Greenwich LifeSciences Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Greenwich LifeSciences Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Greenwich LifeSciences Inc. is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Greenwich LifeSciences Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Greenwich LifeSciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Greenwich LifeSciences Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 25.06, ATR14 : 6.19, CCI20 : -45.13, Chaikin Money Flow : -0.38, MACD : -0.38, Money Flow Index : 79.48, ROC : 2.25, RSI : 32.52, STOCH (14,3) : 9.83, STOCH RSI : 0.06, UO : 27.94, Williams %R : -90.17), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Greenwich LifeSciences Inc. in the last 12-months were:
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.